A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.

doi:10.1038/s41598-021-96986-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.

Scientific reports - 9 Sept 2021

Gimenez Alba Marina, Salman Ahmed M, Marques Rodolfo F, López-Camacho César, Harrison Kate, Kim Young Chan, Janse Chris J, Soares Irene S, Reyes-Sandoval Arturo

Abstract excerpt

Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antibodies, Protozoan

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity, Humoral

Share to Immunogenicity, Vaccine

Share to Malaria Vaccines

Share to Malaria, Vivax

Share to Organisms, Genetically Modified

Share to Plasmodium berghei

Source

Open in PubMed Open full text

Identifiers

PMID: 34504134
DOI: 10.1038/s41598-021-96986-1
PMCID: PMC8429696

Provenance

PubMed metadata and Literature Corpus relationships.